Brief: Moberg Pharma Intends To Distribute And Separately List Bupizenge

Moberg Pharma AB (publ)

06/11/2020 07:09

Nov 6 (Reuters) - Moberg Pharma AB (publ)  MBPH.ST :
    * MOBERG PHARMA INTENDS TO DISTRIBUTE AND SEPARATELY LIST BUPIZENGE ®  (BUPI)
    * MOBERG PHARMA AB (PUBL) - INTENTION TO DISTRIBUTE OPERATIONS OF BUPIZENGE(®) (BUPI) TO
SHAREHOLDERS OF MOBERG PHARMA
    * MOBERG PHARMA AB (PUBL) - ESTIMATES CAPITAL REQUIREMENT TO TAKE BUPIZENGE(®) THROUGH PHASE
3 AT
SEK 60 MILLION.
    * MOBERG PHARMA AB (PUBL) - EVALUATING OPPORTUNITY TO DISTRIBUTE ONCOZENGE ACCORDING TO LEX
ASEA
AND LIST ITS SHARES ON NASDAQ FIRST NORTH GROWTH MARKET
    * MOBERG PHARMA AB (PUBL) - BOARD OF DIRECTORS OF MOBERG PHARMA IS PROPOSING THAT 90 PER
CENT OF
SHARES IN ONCOZENGE BE DISTRIBUTED TO MOBERG PHARMA'S SHAREHOLDERS ACCORDING TO LEX ASEA
    * MOBERG PHARMA AB (PUBL) - PROPOSES THAT TEN (10) ORDINARY SHARES IN MOBERG PHARMA AS OF
RECORD
DATE FOR DISTRIBUTION OF SHARES, SHALL ENTITLE HOLDER TO SUBSCRIBE FOR ONE (1) SHARE IN
ONCOZENGE
    * MOBERG PHARMA AB (PUBL) - TO FINANCE CLINICAL PHASE 3 STUDY AS WELL AS OTHER OPERATIONS,
ONCOZENGE INTENDS TO SECURE TOTAL FINANCING OF APPROXIMATELY SEK 60 MILLION
    * MOBERG PHARMA AB (PUBL) - IN Q1 OF 2021, ONCOZENGE INTENDS TO APPLY TO LIST ITS SHARES FOR
TRADING ON NASDAQ FIRST NORTH GROWTH MARKET.

Source text for Eikon:  ID:nWkr4ZNGF3 
Further company coverage:  MBPH.ST 

 (Gdansk Newsroom)
 ((Gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10;))